For breast tumor, the combination inhibitions of COX-2 and receptor tyrosine kinases could reach between 40% and 60% remaining angiogenesis, which are far better than 81.13% remaining angiogenesis of a single COX-2 inhibition (Figure 3A). The gene discussed is PTGS2; the disease is breast neoplasm.